(function(doc, html, url) { var widget = doc.createElement("div"); widget.innerHTML = html; var script = doc.currentScript; // e = a.currentScript; if (!script) { var scripts = doc.scripts; for (var i = 0; i < scripts.length; ++i) { script = scripts[i]; if (script.src && script.src.indexOf(url) != -1) break; } } script.parentElement.replaceChild(widget, script); }(document, '

Fall in Ki67 marker in response to preoperative Letrozole therapy in early breast cancer

What is it about?

Our study evaluated 119 luminal early breast cancer patients in whom preoperative Letrozole 2.5mg OD was given for a period of 2-4 weeks. The initial Ki67 was noted from the core biopsy specimen, and a post-therapy Ki67 value was obtained from the surgical specimen. The percentage fall was calculated and the factors affecting the same were analysed.

Why is it important?

Our study is one of the first of its kind in India, evaluating the response of different luminal early breast cancer patients to Letrozole therapy. This can help differentiate between good responders and poor responders to endocrine therapy, thus allowing us to tailor adjuvant therapy for each patient

Read more on Kudos…
The following have contributed to this page:
Dhanya Louis
' ,"url"));